MeSH term
Frequency | Condition_Probility | Adult | 26 | 0.0 |
Aged | 12 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage | 2 | 3.0 |
Comparative Study | 10 | 0.0 |
Female | 35 | 0.0 |
Humans | 106 | 0.0 |
Middle Aged | 28 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 63 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 15 | 0.0 |
Survival Rate | 7 | 0.0 |
Animals | 51 | 0.0 |
Cell Line | 10 | 0.0 |
Gastric Mucosa/*enzymology | 2 | 14.0 |
Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Histidine Decarboxylase/*genetics | 14 | 100.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 5 | 1.0 |
Combined Modality Therapy | 10 | 0.0 |
English Abstract | 13 | 0.0 |
*Hematopoietic Stem Cell Transplantation | 7 | 1.0 |
Blotting, Northern | 6 | 0.0 |
DNA Probes | 3 | 0.0 |
Immunohistochemistry | 6 | 0.0 |
Mast Cells/*enzymology | 2 | 7.0 |
Mice | 15 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Rats | 23 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Tumor Cells, Cultured | 7 | 0.0 |
Biological Markers | 2 | 0.0 |
Histamine/*metabolism | 7 | 38.0 |
Histidine Decarboxylase/immunology | 2 | 100.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Macaca | 2 | 2.0 |
Male | 40 | 0.0 |
Cloning, Molecular | 7 | 0.0 |
Genes, Reporter | 4 | 0.0 |
Histamine/*pharmacology | 3 | 8.0 |
Histidine Decarboxylase/*metabolism | 7 | 58.0 |
Macrophages/*metabolism | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Time Factors | 6 | 0.0 |
Transfection | 6 | 0.0 |
Up-Regulation | 3 | 0.0 |
Histamine Antagonists/pharmacology | 4 | 44.0 |
Histidine Decarboxylase/genetics/*metabolism | 2 | 100.0 |
Cells, Cultured | 6 | 0.0 |
Histamine/*physiology | 3 | 100.0 |
Histidine Decarboxylase/*biosynthesis | 4 | 100.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Histamine Release | 6 | 10.0 |
Depression, Chemical | 2 | 1.0 |
Histamine/*biosynthesis | 4 | 66.0 |
Histidine Decarboxylase/metabolism | 12 | 92.0 |
Aged, 80 and over | 2 | 0.0 |
Biopsy | 2 | 0.0 |
In Vitro | 6 | 0.0 |
Child | 7 | 0.0 |
Recurrence | 3 | 0.0 |
Retrospective Studies | 4 | 0.0 |
Treatment Outcome | 7 | 0.0 |
Dose-Response Relationship, Drug | 9 | 0.0 |
Gene Expression | 6 | 0.0 |
Histamine/metabolism | 10 | 29.0 |
In Situ Hybridization | 3 | 0.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Cell Separation | 2 | 0.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Prognosis | 3 | 0.0 |
Risk Factors | 4 | 0.0 |
Cell Division/drug effects | 4 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Histidine Decarboxylase/biosynthesis/genetics | 2 | 100.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
Histidine Decarboxylase/*genetics/metabolism | 2 | 100.0 |
Molecular Sequence Data | 15 | 0.0 |
Disease Progression | 2 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Signal Transduction | 3 | 0.0 |
Benzodiazepines/pharmacology | 2 | 20.0 |
Enterochromaffin Cells/*metabolism | 2 | 66.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Bone Marrow Transplantation | 2 | 0.0 |
Chemotherapy, Adjuvant | 4 | 1.0 |
Child, Preschool | 6 | 0.0 |
Prospective Studies | 2 | 0.0 |
Transplantation, Autologous | 6 | 1.0 |
Mice, Knockout | 2 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*adverse effects | 2 | 4.0 |
Busulfan/administration & dosage | 2 | 11.0 |
Cyclophosphamide/administration & dosage | 4 | 1.0 |
Disease-Free Survival | 3 | 0.0 |
Enzyme Induction/drug effects | 6 | 1.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 4 | 1.0 |
Cell Line, Transformed | 2 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 4 | 0.0 |
Gastric Acid/secretion | 3 | 6.0 |
Pancreatic Hormones/metabolism | 2 | 40.0 |
Receptor, Cholecystokinin B | 3 | 8.0 |
Electric Stimulation | 2 | 0.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Adolescent | 7 | 0.0 |
Histamine N-Methyltransferase/*genetics | 2 | 33.0 |
Kinetics | 7 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Histamine/*blood | 2 | 20.0 |
Protein Binding | 3 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Histamine/analysis | 4 | 44.0 |
Histidine Decarboxylase/*biosynthesis/genetics | 3 | 100.0 |
Injections, Intramuscular | 2 | 1.0 |
Mice, Mutant Strains | 2 | 0.0 |
RANTES/*pharmacology | 3 | 17.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Recombinant Proteins/pharmacology | 5 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Gastrins/*physiology | 3 | 33.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 2 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 2 | 0.0 |
*Mitogen-Activated Protein Kinases | 2 | 0.0 |
Phosphorylation | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
Methylhistidines/pharmacology | 2 | 100.0 |
Breast Neoplasms/*therapy | 2 | 7.0 |
Mice, Inbred Strains | 3 | 0.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Base Sequence | 14 | 0.0 |
Histidine Decarboxylase/genetics | 5 | 100.0 |
Muscarinic Agonists/pharmacology | 2 | 5.0 |
Rats, Sprague-Dawley | 8 | 0.0 |
Skin/metabolism | 2 | 1.0 |
Microscopy, Electron | 4 | 0.0 |
Monocyte Chemoattractant Protein-1/*pharmacology | 2 | 16.0 |
Gastrins/*pharmacology | 3 | 18.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 2 | 1.0 |
Luciferases/biosynthesis | 2 | 2.0 |
Histamine N-Methyltransferase/metabolism | 4 | 66.0 |
Gastrins/physiology | 2 | 33.0 |
Pregnancy | 2 | 0.0 |
Receptors, Cholecystokinin/genetics | 2 | 100.0 |
Gastrins/*blood | 2 | 4.0 |
Calcium/*blood | 2 | 2.0 |
Enzyme Activation | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Gastric Acid/*secretion | 2 | 3.0 |
Chromatography, High Pressure Liquid | 5 | 0.0 |
Molecular Weight | 2 | 0.0 |
Spodoptera | 2 | 0.0 |
Histamine Release/*drug effects | 2 | 6.0 |
Guinea Pigs | 4 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Methylhistidines/*pharmacology | 2 | 100.0 |
Phosphatidylethanolamines/pharmacology | 3 | 25.0 |
Platelet Aggregation Inhibitors/pharmacology | 2 | 3.0 |
Genes, Structural | 2 | 0.0 |
Amine Oxidase (Copper-Containing)/metabolism | 3 | 15.0 |
Nasal Mucosa/enzymology/*metabolism | 2 | 100.0 |
DNA | 2 | 0.0 |
Thapsigargin | 2 | 7.0 |
Chromosome Mapping | 2 | 0.0 |
*Chromosomes, Human, Pair 15 | 2 | 0.0 |
Gastrins/genetics | 2 | 40.0 |
Carboxy-Lyases/*metabolism | 2 | 16.0 |
Cyclophosphamide/administration & dosage/adverse effects | 2 | 9.0 |
Platelet Aggregation/*drug effects | 3 | 2.0 |
Aspirin/pharmacology | 2 | 3.0 |
*Stem Cell Transplantation | 2 | 3.0 |
Infant | 2 | 0.0 |
Cell Fusion | 2 | 0.0 |
DNA Replication | 2 | 0.0 |
Diploidy | 3 | 2.0 |
Antibody Formation | 2 | 0.0 |
Vaccines, Attenuated | 2 | 18.0 |
